Haploidentik Verici Seçimi

Sugita J. HLA-haploidentical stem cell transplantation using posttransplant cyclophosphamide. Int J Hematol. 2019;110(1):30-8. doi: 10.1007/s12185-019-02660-8.

Cusatis R, Litovich C, Feng Z, et al. Current Trends and Outcomes in Cellular Therapy Activity in the United States, Including Prospective Patient-Reported Outcomes Data Collection in the Center for International Blood and Marrow Transplant Research Registry. Transplant Cell Ther. 2024;30(9):917.e1-.e12. doi: 10.1016/j.jtct.2024.06.021.

Passweg JR, Baldomero H, Bader P, et al. Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant. 2017;52(6):811-7. doi: 10.1038/bmt.2017.34.

Spellman SR, Xu K, Oloyede T, et al. Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy - A Report from the CIBMTR. Transplant Cell Ther. 2025;31(8):505-32. doi: 10.1016/j.jtct.2025.05.014.

Elmariah H, Kasamon YL, Zahurak M, et al. Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors. Biol Blood Marrow Transplant. 2018;24(5):1099-102. doi: 10.1016/j.bbmt.2018.02.005.

Vittayawacharin P, Kongtim P, Ciurea SO. Future directions in haploidentical hematopoietic stem cell transplantation. Hematology. 2024;29(1):2366718. doi: 10.1080/16078454.2024.2366718.

Medhasi S, Chantratita N. Human Leukocyte Antigen (HLA) System: Genetics and Association with Bacterial and Viral Infections. J Immunol Res. 2022;2022:9710376. doi: 10.1155/2022/9710376.

Choo SY. The HLA system: genetics, immunology, clinical testing, and clinical implications. Yonsei Med J. 2007;48(1):11-23. doi: 10.3349/ymj.2007.48.1.11.

Kot M, Baj-Krzyworzeka M, Szatanek R, et al. The Importance of HLA Assessment in "Off-the-Shelf" Allogeneic Mesenchymal Stem Cells Based-Therapies. Int J Mol Sci. 2019;20(22). doi: 10.3390/ijms20225680.

EBMT. Clinical Case of the Month – Selection of haploidentical stem cell donors. [Online]: https://www.ebmt.org/ebmt/news/clinical-case-month-selection-haploidentical-stem-cell-donors. Erişim tarihi: 19.04.2026.

Nagler A, Labopin M, Houhou M, et al. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. J Hematol Oncol. 2021;14(1):53. doi: 10.1186/s13045-021-01065-7.

Fuchs EJ, McCurdy SR, Solomon SR, et al. HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide. Blood. 2022;139(10):1452-68. doi: 10.1182/blood.2021013443.

Solomon SR, Aubrey MT, Zhang X, et al. Selecting the Best Donor for Haploidentical Transplant: Impact of HLA, Killer Cell Immunoglobulin-Like Receptor Genotyping, and Other Clinical Variables. Biol Blood Marrow Transplant. 2018;24(4):789-98. doi: 10.1016/j.bbmt.2018.01.013.

Ciurea SO, Al Malki MM, Kongtim P, et al. The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. Bone Marrow Transplant. 2020;55(1):12-24. doi: 10.1038/s41409-019-0499-z.

Shaw BE, Logan BR, Spellman SR, et al. Development of an Unrelated Donor Selection Score Predictive of Survival after HCT: Donor Age Matters Most. Biol Blood Marrow Transplant. 2018;24(5):1049-56. doi: 10.1016/j.bbmt.2018.02.006.

DeZern AE, Franklin C, Tsai HL, et al. Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide. Blood Adv. 2021;5(5):1360-8. doi: 10.1182/bloodadvances.2020003922.

Nagler A, Labopin M, Swoboda R, et al. Young (<35 years) haploidentical versus old (≥35 years) mismatched unrelated donors and vice versa for allogeneic stem cell transplantation with post-transplant cyclophosphamide in patients with acute myeloid leukemia in first remission: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2024;59(11):1552-62. doi: 10.1038/s41409-024-02400-5.

Marcoux C, Marin D, Ramdial J, et al. Younger haploidentical donor versus older matched unrelated donor for patients with AML/MDS. Am J Hematol. 2023;98(5):712-9. doi: 10.1002/ajh.26870.

Mehta RS, Marin D, Alousi A, et al. Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type. Blood Adv. 2023;7(8):1594-603. doi: 10.1182/bloodadvances.2022009240.

Wang Y, Chang YJ, Xu LP, et al. Who is the best donor for a related HLA haplotype-mismatched transplant? Blood. 2014;124(6):843-50. doi: 10.1182/blood-2014-03-563130.

Canaani J, Savani BN, Labopin M, et al. Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation. Am J Hematol. 2018;93(2):246-53. doi: 10.1002/ajh.24963.

Ciurea SO, Shah MV, Saliba RM, et al. Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant. 2018;24(6):1232-6. doi: 10.1016/j.bbmt.2017.09.005.

Zhang C, Chen XH, Zhang X, et al. Stem cell collection in unmanipulated HLA-haploidentical/mismatched related transplantation with combined granulocyte-colony stimulating factor-mobilised blood and bone marrow for patients with haematologic malignancies: the impact of donor characteristics and procedural settings. Transfus Med. 2010;20(3):169-77. doi: 10.1111/j.1365-3148.2010.00990.x.

Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488-98. doi: 10.1056/NEJMoa1408617.

Dzierzak-Mietla M, Markiewicz M, Siekiera U, et al. Occurrence and Impact of Minor Histocompatibility Antigens' Disparities on Outcomes of Hematopoietic Stem Cell Transplantation from HLA-Matched Sibling Donors. Bone Marrow Res. 2012;2012:257086. doi: 10.1155/2012/257086.

Stern M, Brand R, de Witte T, et al. Female-versus-male alloreactivity as a model for minor histocompatibility antigens in hematopoietic stem cell transplantation. Am J Transplant. 2008;8(10):2149-57. doi: 10.1111/j.1600-6143.2008.02374.x.

Frassoni F, Labopin M, Gluckman E, et al. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time--a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT). Bone Marrow Transplant. 1996;17(1):13-8.

McCurdy SR, Zhang MJ, St Martin A, et al. Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide. Blood Adv. 2018;2(3):299-307. doi: 10.1182/bloodadvances.2017014829.

van Rood JJ, Zhang L, van Leeuwen A, et al. Neonatal tolerance revisited. Immunol Lett. 1989;21(1):51-4. doi: 10.1016/0165-2478(89)90011-4.

Claas FH, Gijbels Y, van der Velden-de Munck J, et al. Induction of B cell unresponsiveness to noninherited maternal HLA antigens during fetal life. Science. 1988;241(4874):1815-7. doi: 10.1126/science.3051377.

van Rood JJ, Loberiza FR, Jr., Zhang MJ, et al. Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling. Blood. 2002;99(5):1572-7. doi: 10.1182/blood.v99.5.1572.

Tang FF, Zhao XY, Huo MR, et al. Comparison of the clinical outcomes between NIMA-mismatched and NIPA-mismatched haploidentical hematopoietic stem cell transplantation for patients with hematological malignancies. Bone Marrow Transplant. 2021;56(11):2723-31. doi: 10.1038/s41409-021-01382-y.

Molitor ML, Burlingham WJ. Immunobiology of exposure to non-inherited maternal antigens. Front Biosci. 2007;12:3302-11. doi: 10.2741/2313.

Scholl S, Klink A, Mügge LO, et al. Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch. Transfusion. 2005;45(10):1676-83. doi: 10.1111/j.1537-2995.2005.00578.x.

Canaani J, Savani BN, Labopin M, et al. Impact of ABO incompatibility on patients' outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT. Haematologica. 2017;102(6):1066-74. doi: 10.3324/haematol.2016.160804.

Ljungman P, Brand R, Hoek J, et al. Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation. Clin Infect Dis. 2014;59(4):473-81. doi: 10.1093/cid/ciu364.

Khimani F, Ranspach P, Elmariah H, et al. Increased Infections and Delayed CD4(+) T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic Transplantation. Transplant Cell Ther. 2021;27(11):940-8. doi: 10.1016/j.jtct.2021.07.023.

Atilla E, Atilla PA, Bozdağ SC, et al. A review of infectious complications after haploidentical hematopoietic stem cell transplantations. Infection. 2017;45(4):403-11. doi: 10.1007/s15010-017-1016-1.

Chorão P, Henriques M, Villalba M, et al. Cytomegalovirus Reactivations in Allogeneic Hematopoietic Stem Cell Transplantation from HLA-Matched and Haploidentical Donors with Post-Transplantation Cyclophosphamide. Transplant Cell Ther. 2024;30(5):538.e1-.e10. doi: 10.1016/j.jtct.2024.01.082.

Cesaro S, Crocchiolo R, Tridello G, et al. Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT. Bone Marrow Transplant. 2018;53(4):422-30. doi: 10.1038/s41409-017-0016-1.

Huang Y, Luo C, Wu G, et al. Effects of donor-specific antibodies on engraftment and long-term survival after allogeneic hematopoietic stem cell transplantation-A systematic review and meta-analysis. Bone Marrow Transplant. 2023;58(5):544-51. doi: 10.1038/s41409-023-01932-6.

Yoshihara S, Maruya E, Taniguchi K, et al. Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT. Bone Marrow Transplant. 2012;47(4):508-15. doi: 10.1038/bmt.2011.131.

Chang YJ, Zhao XY, Xu LP, et al. Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets. J Hematol Oncol. 2015;8:84. doi: 10.1186/s13045-015-0182-9.

Ciurea SO, Thall PF, Milton DR, et al. Complement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015;21(8):1392-8. doi: 10.1016/j.bbmt.2015.05.001.

Ciurea SO, de Lima M, Cano P, et al. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation. 2009;88(8):1019-24. doi: 10.1097/TP.0b013e3181b9d710.

Ciurea SO, Al Malki MM, Kongtim P, et al. Treatment of allosensitized patients receiving allogeneic transplantation. Blood Adv. 2021;5(20):4031-43. doi: 10.1182/bloodadvances.2021004862.